Regeneron shares drop as higher-dose Eylea drug misses sales estimates

Published on 31 Oct 2024 on Reuters

, opens new tab on Thursday reported weaker-than-expected quarterly sales of the higher dose version...

Read the rest of the article

Start tracking your investments with Statfolio

Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarte...

Insider Monkey · via Yahoo Finance 1 Nov 2024

On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported third-quarter adjusted EPS of...

Benzinga · via Yahoo Finance 31 Oct 2024

, opens new tab on Thursday reported weaker-than-expected quarterly sales of the higher dose vers...

Reuters 31 Oct 2024

Research and development expenses reflect a commitment to innovation, with a significant increase...

GuruFocus.com · via Yahoo Finance 31 Oct 2024

A recent Federal Court decision confirmed that the Family Medical Leave Act (FMLA) does not requi...

Central New York Business Journal 23 Oct 2024

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following...

Reuters 22 Oct 2024

On October 10, the US Department of Justice (DOJ) announced that Teva Pharmaceuticals USA Inc. an...

The National Law Review 18 Oct 2024

We recently compiled a list of the 10 Buzzing AI Health Stocks. In this article, we are going to...

Insider Monkey · via Yahoo Finance 8 Oct 2024

We recently made a list of Morgan Stanley’s Best Overweight & Quality Stocks: Top 25 Stocks. In t...

Insider Monkey · via Yahoo Finance 8 Oct 2024

On September 3, 2024, Arthur Ryan, Director at Regeneron Pharmaceuticals Inc (NASDAQ:REGN), execu...

GuruFocus.com · via Yahoo Finance 28 Aug 2024